utrophin Antibody (3B6): sc-33699
- utrophin Antibody (3B6) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 261-371 of human utrophin
- recommended for detection of utrophin of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See utrophin (8A4): sc-33700 for utrophin antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for utrophin Antibody (3B6) for WB and IHC(P) applications. These reagents are now offered in bundles with utrophin Antibody (3B6) (see ordering information below).
QUICK LINKS
SEE ALSO...
Utrophin Antibody (3B6) is a mouse monoclonal IgG1 antibody that detects utrophin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Utrophin is a crucial structural protein that shares significant homology with dystrophin and plays a vital role in anchoring the cytoskeleton to the plasma membrane, particularly in muscle and brain tissues. Localization to the inner surface of the plasma membrane is essential for maintaining cellular integrity and facilitating communication between the cytoskeleton and the extracellular matrix. Notably, utrophin undergoes alternative splicing, which allows interaction with various proteins, contributing to functional versatility. Anti-utrophin antibody (3B6) serves as an invaluable tool for researchers investigating molecular mechanisms underlying muscular dystrophies, where utrophin upregulation has been shown to mitigate pathological effects associated with dystrophin absence, highlighting potential therapeutic applications.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
utrophin Antibody (3B6) References:
- The role of utrophin in the potential therapy of Duchenne muscular dystrophy. | Perkins, KJ. and Davies, KE. 2002. Neuromuscul Disord. 12 Suppl 1: S78-89. PMID: 12206801
- Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening. | Moorwood, C. and Khurana, TS. 2013. Expert Opin Drug Discov. 8: 569-81. PMID: 23473647
- Utrophin Compensates dystrophin Loss during Mouse Spermatogenesis. | Chen, HC., et al. 2017. Sci Rep. 7: 7372. PMID: 28785010
- Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. | Song, Y., et al. 2019. Nat Med. 25: 1505-1511. PMID: 31591596
- Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression. | Georgieva, AM., et al. 2022. Nat Commun. 13: 4184. PMID: 35859073
- Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review. | Szwec, S., et al. 2024. BioDrugs. 38: 95-119. PMID: 37917377
- Gene therapy delivered micro-dystrophins co-localize with transgenic utrophin in dystrophic skeletal muscle fibers. | Krishna, S., et al. 2024. Neuromuscul Disord. 36: 1-5. PMID: 38301403
- Improved mitochondrial function in the hearts of sarcolipin-deficient dystrophin and utrophin double-knockout mice. | Mareedu, S., et al. 2024. JCI Insight. 9: PMID: 38564291
- Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. | Wu, R., et al. 2022. Fundam Res. 2: 885-893. PMID: 38933385
- Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPsc-derived CMs. | Andrysiak, K., et al. 2024. Mol Ther Nucleic Acids. 35: 102247. PMID: 39035791
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
utrophin Antibody (3B6) | sc-33699 | 200 µg/ml | $322.00 | |||
utrophin Antibody (3B6): m-IgG Fc BP-HRP Bundle | sc-538931 | 200 µg Ab; 10 µg BP | $361.00 | |||
utrophin Antibody (3B6): m-IgG1 BP-HRP Bundle | sc-541160 | 200 µg Ab; 20 µg BP | $361.00 |